Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ventrus to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
NEW YORK , May 15, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison , Chairman and Chief Executive Officer, will be presenting at the Bank of
View HTML
Toggle Summary Ventrus Biosciences Announces Positive Results From Pivotal Phase 3 Trial of Diltiazem (VEN 307) in Patients With Anal Fissures
Treatment Arms Show Significant Improvement Over Placebo in Three Major Outcomes Adverse Events Similar Between Treatment Arms and Placebo Company to Host Conference Call and Presentation Today, May 14 , at 10:00 a.m. ET NEW YORK , May 14, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc.
View HTML
Toggle Summary Ventrus Biosciences Reports First Quarter 2012 Financial Results
NEW YORK , May 9, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today reported financial results for the first quarter ended March 31, 2012 . "Ventrus has achieved several important milestones in recent months, namely the completion of enrollment in pivotal Phase 3 clinical
View HTML
Toggle Summary Ventrus to Present at the 37th Annual Deutsche Bank Health Care Conference
NEW YORK , May 1, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison , Chairman and Chief Executive Officer, will be presenting at the 37 th Annual
View HTML
Toggle Summary Ventrus Biosciences Completes Enrollment of Pivotal Phase 3 Trial of Iferanserin (VEN 309) in Patients With Hemorrhoidal Disease
Results Are Anticipated in Late June to Early July - 2012
View HTML
Toggle Summary Ventrus Announces Two Studies Addressing Hemorrhoid Disease to be Presented at Digestive Disease Week Conference
NEW YORK , March 8, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced today that two abstracts submitted to the Digestive Disease Week conference (DDW), to be held in San Diego May 19-22 , were accepted for presentation. Both abstracts present data from the omnibus patient
View HTML
Toggle Summary Ventrus to Present at the 24th Annual ROTH OC Growth Stock Conference
NEW YORK , March 5, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison , Chairman and Chief Executive Officer, will be presenting at the 24 th Annual
View HTML
Toggle Summary Ventrus to Present at Cowen and Company 32nd Annual Health Care Conference
NEW YORK , Feb. 28, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison , Chairman and Chief Executive Officer, will be presenting at the Cowen and
View HTML
Toggle Summary Ventrus Announces Publication of Prior Phase 2b Study on the Safety and Efficacy of Iferanserin in the Treatment of Hemorrhoid Disease
NEW YORK , Jan. 13, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), today announced the online publication of the prior Phase 2b study utilizing iferanserin (VEN 309), its novel investigational drug for the treatment of symptomatic hemorrhoids, in the peer reviewed journal
View HTML
Toggle Summary Ventrus BioSciences Completes Enrollment of Pivotal Phase 3 Trial of Diltiazem (VEN 307) in Patients With Anal Fissures
Expects to Deliver Top Line Results From Pivotal Trial in May-2012
View HTML